Prescription Drugs Projected to Pass $897 Billion by 2015
Though usually shielded from economic cycles, the pharmaceutical drug industry in the U.S. and Europe is expected to slow through 2010. Instead, due to the economic decline, emerging markets such as Brazil, Russia, India and China are projected to grow. The industry has shifted from the flat mature market performance that occurred as a result of the expiration of drug patents and generics entering the marketplace, as well as a slowdown in consumer spending; however, the report also suggests that some areas may not be affected by market characteristics. Oncology or cancer drugs represent the fastest-growing therapeutic class followed closely by respiratory agents and lipid regulators.

Small Molecule Kinase Inhibitor Drugs Stretches to $16.2 Billion by 2015

Treatments for cancer and non-oncology disease will expand the small molecule kinase inhibitors market, a class of drugs that develops the potential for inhibiting specific enzymes in selected kinase proteins, of which there are over 500 types in the human body. The rise in this class of drugs is due to the promise of their impact on treating tumors and the potential for multi-targeted kinase inhibitors in combination with other drug therapies. Current leaders are Amgen Inc.; Novartis; AstraZeneca Plc; and Genentech.

Nanomedicine Market to Pass $160 Billion by 2015
The unique properties of nanoparticles and their ability to be used in the course of disease diagnosis and treatment offer a robust opportunity in this market. The nanomedicine segment includes nanodrug delivery, nanoanalytical contrast reagents, nanobiomaterials and nanopharmaceuticals. The market is fragmented but several key players are Abraxis BioScience Inc., Crucell N.V.; Elan Corporation Plc; Nanosphere Inc. and Wyeth Pharmaceuticals.

To learn more, visit www.strategyr.com

Back to HCB News

More Industry Headlines